EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Genomic and Transcriptomic Landscape of Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Multicenter Study

Yan Li, Ze-Lin Weng, Han-Xiao Fei, Hai-Feng Li, Yi-Na Liu, Le-Le Zhang, Qiong Zhang, Xin Weng, Yuan-Yuan Wang, Wen-Yong Huang, Zhi-Xing Cao, Kai-Yan Yang und 8 weitere

Modern Pathology · 2025

DOI: 10.1016/j.modpat.2025.100864 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Pathology, 2025. Verfasst von Yan Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Dendritic Cell Sarcoma, Follicular, Epstein-Barr Virus Infections, Transcriptome, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Shenzhen Basic Research Program, Key Technologies Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV+ IFDCS) is a rare indolent malignant neoplasm, which occurs almost exclusively in the liver or spleen and may arise from a common EBV-infected mesenchymal cell that differentiates along the follicular or fibroblastic dendritic cell pathway. Despite its rarity, it presents a pressing need for an improved understanding of its genetic underpinnings and potential treatment strategies for recurrent or disseminated cases. To address this, we conducted comprehensive whole-exome sequencing and transcriptome sequencing (mRNA-seq) analyses on 31 and 6 cases of EBV+ IFDCS, respectively, collected from multiple centers in China. We also compared the genetic features of EBV+ IFDCS with those of other EBV-associated malignancies. Our analyses revealed a relatively high somatic mutation rate and widespread copy number variations affecting the major histocompatibility complex-I/II in EBV+ IFDCS. Integrated mutational profiling identified key signaling pathways involved in epigenetic regulation, NF-κB signaling, RTK/RAS/PI(3)K, and the Hippo pathway. Furthermore, we identified several frequently altered genes that could serve as potential therapeutic targets in EBV+ IFDCS. Transcriptomic analysis unveiled significant upregulation of pathways related to virus infection, immune responses, and multiple immune checkpoint genes in EBV+ IFDCS. Comparative analysis demonstrated clear genetic distinctions between EBV+ IFDCS and other EBV-associated tumors. In conclusion, our study provides comprehensive insights into the unique genomic and transcriptomic landscape of EBV+ IFDCS. We have identified multiple genetic alterations that likely contribute to the development and progression of this malignancy. Our results suggest that targeted therapy and immune checkpoint inhibitors may hold promise as potential therapeutic approaches for patients with recurrent or disseminated EBV+ IFDCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic Cell Sarcoma, FollicularEpstein-Barr Virus InfectionsTranscriptomeBiomarkers, TumorHumansMaleFemaleMiddle AgedAdultHerpesvirus 4, HumanAgedExome SequencingMutationGene Expression Profiling

Stichwörter der Autor:innen

Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcomagenomicsimmune checkpoint therapytargeted therapytranscriptomicstreatment strategy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Pathology, Sun Yat-sen University Cancer C…
  • Shenzhen Key Laboratory for Systems Medicine in Inflammatory Diseases, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Sun Yat-sen University, Shenzhen, China.
  • Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Pathology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
  • Department of Pathology, Shenzhen Second People's Hospital, Shenzhen, China.

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Shenzhen Basic Research Program
  • Key Technologies Research and Development Program
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities
  • Sun Yat-sen University

Zitieren

APA

Li, Y., Weng, Z. L., Fei, H. X., Li, H. F., Liu, Y. N., Zhang, L. L., Zhang, Q., Weng, X., Wang, Y. Y., Huang, W. Y., Cao, Z. X., Yang, K. Y., Chen, X. L., Gao, J., Yang, W. S., Liu, F., Yong, J. J., Yun, J. P., Zhang, H., & Huang, Y. H. (2025). Genomic and Transcriptomic Landscape of Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Multicenter Study. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100864

Vancouver

Li Y, Weng ZL, Fei HX, Li HF, Liu YN, Zhang LL, et al. Genomic and Transcriptomic Landscape of Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Multicenter Study. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100864

BibTeX
@article{Li2025,
  author = {Li, Yan and Weng, Ze-Lin and Fei, Han-Xiao and Li, Hai-Feng and Liu, Yi-Na and Zhang, Le-Le and Zhang, Qiong and Weng, Xin and Wang, Yuan-Yuan and Huang, Wen-Yong and Cao, Zhi-Xing and Yang, Kai-Yan and Chen, Xi-Liang and Gao, Jie and Yang, Wen-Sheng and Liu, Fang and Yong, Juan-Juan and Yun, Jing-Ping and Zhang, Hua and Huang, Yu-Hua},
  title = {Genomic and Transcriptomic Landscape of Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma: A Multicenter Study},
  journal = {Modern Pathology},
  year = {2025},
  doi = {10.1016/j.modpat.2025.100864}
}
Kostenlos starten →